Clinical OMICS

MAY-JUN 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/827649

Contents of this Issue

Navigation

Page 19 of 47

18 Clinical OMICs May/June 2017 www.clinicalomics.com Diagnostics Almac Study IDs Patients at Risk for Mestastatic Prostate Cancer Ventana PD-L1 Assay Attains CE Label Expansion to Inform Lung Cancer Treatment Decisions In early May, Roche launched the Ven- tana PD-L1 (SP263) Assay as an in vitro diagnostic test for anti-PD-1 drug Key- truda (pembrolizumab) to identify untreated and previously treated meta- static non-small cell lung cancer (NSCLC) patients eligible for the immunotherapy. The assay is available in countries accept- ing the CE mark. "Roche first launched the VENTANA PD-L1 (SP263) Assay in September 2016 as a diagnostic test for previously treated metastatic NSCLC patients in countries accepting the CE mark. "We are very pleased to expand its application to include patients being considered for Keytruda immunother- apy as the first line of treatment," said Ann Costello, head of Roche Tissue Diag- nostics. " The assay provides new insights into possible treatment options for this potentially deadly disease." Roche will continue to purs ue regu- latory approval for the Ventana PD-L1 (SP263) Assay in other cancer indications and in other geographies. Almac Diagnostics recently pub- lished the results of a validation study demonstrating the effectiveness of their "Prostate Metastatic Cancer Assay" for identifying prostate cancer patients at a higher risk of metastatic disease following surgical resection. While standard treatments for local- ized prostate cancer, including surgi- cal removal of the prostate gland and radical radiotherapy, cure the major- ity of patients, approximately 10% to 20% will develop metastatic disease that will eventually limit their lifes- pan. The ability to identify high-risk patients would make it possible for cli- nicians to offer additional, potentially life-saving, treatment options. "The problem we have is that current clin- ical factors are informative, but they don't tell us the whole story," Richard Kennedy, M.D., Ph.D., vice president and medical director of Almac Diag- nostics, commented on the motivation behind the assay's development. "We had the hypothesis that there may be a molecular subgroup of pros- tate cancers that have the ability to metastasize," Kennedy elaborated. To test this hypothesis, Almac Diagnos- tics analyzed large archives of forma- lin-fixed paraffin-embedded (FFPE) tissue from primary tumors that led to either metastatic or non-metastatic disease. These analyses revealed a gene expression signature of seventy genes that formed the basis of the Prostate Metastatic Cancer Assay. The study, published in the Journal of European Urology, details a collab- orative, multi-center effort to inde- pendently validate the assay using 322 radical prostatectomy samples. The study's authors used a measurement termed hazard ratio (HR) to assess the assay's ability to identify high-risk patients. The assay, independent of any additional clinical factors, had a HR of 3.2; thus, a patient who tested positive for the gene expression signa- ture identified by the assay would be approximately three times more likely to develop metastatic disease. When applied to the validation study data- set, the standard risk model used in the U.S., CAPRA-S, which combines multiple clinical factors, had a HR of 2.7. Combined the two prognostic tools achieved an overall HR of 7.5 — indicating a much greater ability to identify high-risk patients. Almac intends to publish addi- tional studies that will demonstrate the assay's effectiveness when used with biopsy samples collected prior to radical radiotherapy, and the ability to transfer the assay to different commer- cial platforms.—Meghaan Ferreira prnewswire.co.uk VENTANA PD-L1 (SP263) Assay staining in non-small cell lung cancer (NSCLC) with membranous and cytoplasmic staining of the tumor cells. MedicalArtInc / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2017